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Abstract Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to
 the growth of secondary tumor implants and metastasis. While former studies have indicated that 
T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifes-
tation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor 
serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as 
an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal 
proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. 
In this work, we have extended our previous findings demonstrating that a periodic intravenous administration 
of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two 
different metastatic murine tumors and decreased the rate of death from 100% up to 25% in tumor-excised mice 
that already exhibited established metastases at the time of surgery. These anti-metastatic effects were achieved 
even at very low concentrations and without displaying any detectable toxic-side effects, suggesting that the use 
of meta-tyrosine may help to develop new and less harmful means of managing malignant diseases, especially 
those aimed to control the growth of metastases that is the most serious problem in cancer pathology. 
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Resumen Meta-tirosina. Un poderoso agente anti-metastásico sin efectos tóxicos colaterales detectables.
 La resistencia concomitante antitumoral (RC) es el fenómeno según el cual un individuo portador 
de tumor inhibe el crecimiento de implantes tumorales secundarios y metástasis. Si bien desde hace tiempo se 
sabe que la RC inducida por tumores inmunogénicos de pequeño tamaño es generada por mecanismos inmu-
nológicos dependientes de células T, por otro lado, la manifestación más universal de la RC, generada tanto 
por tumores inmunogénicos como no-inmunogénicos de gran tamaño, había sido asociada con un (unos) factor 
sérico antitumoral cuya naturaleza permaneció elusiva por años. En un trabajo reciente, nuestro grupo de trabajo 
identificó este factor como la mezcla equi-molar de meta-tirosina y orto-tirosina, dos isómeros de tirosina que no 
están presentes en proteínas normales y que demostraron ser responsables del 90% y 10%, respectivamente, 
de la actividad antitumoral total del suero. En este trabajo, continuamos nuestras investigaciones demostrando 
que la administración periódica de meta-tirosina reducía drásticamente el número de metástasis pulmonares y 
hepáticas en ratones portadores de dos tumores murinos altamente metastásicos y disminuía dramáticamente la 
mortandad (de 100% a 25%) de ratones con metástasis ya establecidas al momento de la extirpación quirúrgica 
del tumor. Estos efectos anti-metastásicos se lograron aun con muy bajas concentraciones de meta-tirosina y 
sin efectos tóxicos perceptibles, lo que sugiere que su uso puede ayudar a diseñar nuevas y menos nocivas 
estrategias para el tratamiento del cáncer, especialmente aquellas destinadas a controlar el crecimiento metas-
tásico, que es el problema más grave en la enfermedad oncológica. 
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Concomitant tumor resistance (CR) is the phenomenon 
according to which a tumor-bearing host inhibits or retards 
the growth of secondary tumor implants. It was first de-
scribed by Ehrlich in 19061 but, apart from a few isolated 
papers2, 3 this phenomenon remained virtually forgotten 
for about 60 years4, 5. After its renascence, some groups 
have studied this phenomenon demonstrating that both 
immunogenic and non-immunogenic tumors can induce 
CR in different animal models such as mice, rats and ham-
sters6-8. However, CR has not received much attention as 
compared with other areas of cancer research despite the 
fact that it has been detected in association with human 
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cancer and despite its relevance to the mechanisms of me-
tastases control, taking into account that metastases could 
be considered as secondary tumor implants developed 
spontaneously during the primary tumor growth. In this 
sense, clinical and experimental evidence accumulated 
throughout the years has suggested that the removal of 
human and murine tumors may, upon certain circum-
stances, be followed by an abrupt increase in metastatic 
growth9, suggesting that a primary tumor could exert a 
controlling action on its metastases. Metastatic growth is 
considered a far more serious problem than the original 
tumor because, for most cases, they ultimately prove 
to be fatal for the patient. In effect, prior to metastases, 
most cancers can be cured surgically and 5-year survival 
rates are about 90%. However, when a tumor has spread 
to different sites, those rates, even using some forms of 
systemic therapy such as chemotherapy, often fall below 
15%10. Therefore, the understanding of the mechanisms 
underlying the phenomenon of CR could have a significant 
impact in the management of the malignant diseases.
Different hypothesis have been proposed to explain 
the phenomenon of CR. According to the immunological 
hypothesis, the growth of a tumor generates a specific 
antitumor immune response which even though it is not 
strong enough to inhibit the primary tumor growth, is still 
capable of preventing the development of a relatively 
small secondary tumor inoculum. The immunological 
hypothesis was originally proposed by Bashford in 19082 
which, in turn, coined the term “concomitant immunity” by 
which this phenomenon has been known in the past. This 
interpretation is supported by solid evidence mainly based 
on experiments with strongly immunogenic murine tumors 
induced by chemical agents or viruses8. However, it does 
not provide a satisfactory explanation for the fact that CR 
has also been observed in association with spontaneous 
murine tumors of non-detectable immunogenicity7, 11. As 
for non-immunological explanations, basically two hypoth-
eses have been formulated. Ehrlich1 believed that nutrients 
essential for tumor growth are consumed by the primary 
tumor, making it difficult for a second implant to develop 
(atrepsis theory). Others7, 12 have postulated that the 
primary tumor produce –or induce the production of– anti-
proliferative nonspecific substances or anti-angiogenic 
molecules which limit the replication of tumor cells of the 
second inoculum. These non-immunological hypotheses 
can offer a putative explanation for the phenomenon of 
CR induced by non-immunogenic tumors but not for the 
specific inhibition of secondary tumor implants observed 
during the growth of immunogenic tumors.
For the last 30 years, we have studied, in our labora-
tory, the phenomenon of CR associated with the growth 
of 20 murine tumors displaying widely different degrees 
of immunogenicity, in an attempt to integrate the differ-
ent hypotheses into a coherent picture. Our results7, 8, 
11 demonstrated that, two temporally separate peaks of 
CR are generated during primary tumor growth. The first 
peak was only induced by immunogenic tumors of small 
size (≤ 500 mm3); it was tumor-specific and thymus-
dependent and a typical immunological rejection was 
observed histologically at the site of the second tumor 
implant undergoing CR. On the other hand, the second 
peak of CR was induced by both immunogenic and non-
immunogenic large tumors (≥ 2000 mm3); it was tumor-
non-specific and thymus-independent and the inhibition 
of the secondary tumor was not associated with an im-
munological cell infiltration, but with the presence of viable 
but non-infiltrating tumor cells (dormant tumor) located at 
the inoculation site between the skin and the muscular 
layer. Some years ago, an intermediate peak of CR was 
reported to be associated with a particular type of mild-
sized tumors (1000-1500 mm3) that restrain secondary 
tumors indirectly, by limiting tumor neovascularization12. 
Although the mechanisms associated with the first and 
intermediate peaks of CR have been elucidated as T cell–
dependent and angiostatin-dependent, respectively, the 
molecular basis of the most universal manifestation of CR, 
that is, the second peak, remained an enigma for many 
years. In former studies, we demonstrated that the second 
peak of CR correlated with the activity of a serum factor(s) 
that inhibited the in vitro and in vivo proliferation of tumor 
cells and that was unrelated to other well characterized 
growth-inhibitory molecules such as interferons, TNF-α, 
TGF-β, angiostatin, endostatin, etc., taking into account 
the larger molecular weight of the latter and other physical 
and biological properties7, 8. In a recently published work13, 
starting from mice bearing a non-immunogenic lymphoma 
(called LB), that produces the strongest second peak of 
CR among all our tumor models, we identified such serum 
factor(s) as meta-tyrosine and ortho-tyrosine, two isomers 
of tyrosine that it is thought to be absent from normal 
proteins. Meta-tyrosine and ortho-tyrosine proved to be 
responsible for 90% and 10%, respectively, of the total 
serum anti-tumor activity, as demonstrated by in vitro and 
in vivo experiments on the growth of three different murine 
tumors that induce CR and on the growth of established 
spontaneous metastases generated by a fourth tumor that 
does not induce CR but is sensitive to the CR induced by 
other tumors.
In this work, in order to extend our previous observa-
tions concerning the anti-metastatic role of meta-tyrosine 
(herein we used only meta-tyrosine because its anti-tumor 
power proved to be 10 times more robust than that of 
ortho-tyrosine), we have carried out the following series 
of experiments:
a) Study of the dose-response of meta-tyrosine ad-
ministration on the growth of spontaneous metastases 
generated by the presence of two highly metastatic mu-
rine tumors: the mammary carcinomas C7HI and LMM3, 
kindly provided by Dra. C. Lanari (Instituto de Biología 
y Medicina Experimental, Buenos Aires, Argentina) and 
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Dr. L. Colombo (Instituto Ángel Roffo, Buenos Aires, 
Argentina), respectively. 
b) Evaluation of the effect of meta-tyrosine on the sur-
vival of LMM3-excised mice exhibiting established lung 
metastases at the time of surgery.
c) Analysis of putative cytotoxic side-effects associated 
with a periodic administration of meta-tyrosine.
a)  BALB/c mice bearing a subcutaneous (s.c.) C7HI tu-
mor for 40 days were divided in four groups that received, 
between days 40 and 60, a daily intravenous (i.v.) injection 
of three different doses of meta-tyrosine (3.3; 33 and 67 
mg/kg) or saline (control). A fifth group was sacrificed at 
day 40 to evaluate the number of metastases at the onset 
of treatment. At day 60, all treated and control mice were 
sacrificed and macroscopic (diameter ≥ 0.1 mm, x 10) 
and microscopic (diameter < 0.1 mm, H&E x 100) lung 
metastases were counted. As shown in Table 1, all the 
doses of meta-tyrosine reduced drastically the number of 
macroscopic lung metastases as compared with controls. 
In fact, the higher dose decreased the number of metas-
tases that had been observed at the onset of treatment 
(Table 1). Microscopic lung metastases (data not shown) 
as well as macroscopic hepatic metastases were also 
significantly reduced at the end of treatment; hepatic me-
tastases (median [range]) in control: 8 [3-18] vs. treated 
(67 mg/kg/day): 0 (p < 0.001, Mann-WhitneyU-test). 
Similarly, BALB/c mice bearing a s.c. LMM3 tumor for 25 
days were divided in three groups that received, between 
25 and 45 days, a daily i.v. injection of meta-tyrosine (3.3 
and 67 mg/kg) or saline. A fourth group was sacrificed at 
day 25 to evaluate the number of metastases at the onset 
of treatment. At day 45, all treated and control mice were 
sacrificed and metastases counted. As shown in Table 1 
all the doses of meta-tyrosine reduced drastically the 
number of macroscopic lung metastases as compared with 
controls (Table 1). Microscopic lung metastases (data not 
shown) as well as macroscopic hepatic metastases were 
also significantly reduced at the end of treatment; hepatic 
metastases in control: 10 [5-16] vs. treated (67 mg/kg/day): 
0 (p < 0.001, Mann-Whitney U-test). It is worth to note that 
the administration of meta-tyrosine by the intra-peritoneal 
(i,p.) route was not effective to restrict metastatic growth.
b) Twenty five BALB/c mice were inoculated sc with 2 
x 105 LMM3 tumor cells. Eighteen days later, 19 tumor-
bearing mice were surgically operated to remove the 
tumor and the remaining 6 were sacrificed to evaluate the 
number of lung metastases at the time of surgery (mean 
[range] = 6 [3-10]). Then, the tumor-excised mice were 
divided into two groups. One group (n = 8) received, for 
the following consecutive 35 days, a daily i.v. injection of 
meta-tyrosine (67 mg/kg). The other group (n = 9) received 
saline. The surgical excision was very satisfactory since 
no tumor relapsed. As shown in Fig. 1, all controls died 
exhibiting high number of lung and hepatic metastases 
at 43 ± 8 days (mean ± standard error) after surgery. 
In contrast only two treated-mice died, while the other 6 
mice remained alive without exhibiting signs of local or 
metastatic disease for, at least, eight months after surgery 
(p < 0.001 Log Rank test).   
c) The highest dose of meta-tyrosine (67 mg/kg) used 
in our previous experiments was administered daily by the 
i.v. route for 42 days in BALB/c mice. At day 42, a sample 
of mice was sacrificed and the following organs - skin, 
liver, kidney, spleen, lung, bone marrow, small and large 
intestine – were investigated histopathologically. Neither 
histologic nor cytologic alterations were detected in any 
case, even when organs with high rate of renewal such 
as skin, bone marrow or small intestine were studied. 
Hematologic cell populations in blood and lymphoid popu-
lations in lymph nodes and spleen were not altered either, 
TABLE 1.– Effect of periodic i.v. administration of meta-tyrosine on the number of 
macroscopic lung metastases generated by C7HI and LMM3 tumor-bearing mice  
  N° of lung metastases (median [range])
Tumor Control Meta-tyrosine (mg/kg/day)
  3.3 33 67 
C7HI 44.5 [17-119] 19.4 [5-34]a 14.2 [5-29]b 9.3 [2-26]c  
 (n = 40) (n = 23) (n = 32) (n = 18)
LMM3 60.0 [44-100] 30.5 [9-64]a ND  17.3 [5-33]c
 (n = 15) (n = 10    (n = 7)
Number of macroscopic lung metastases at the onset of treatment: 17.3 [9-32] for C7HI (n = 17, 
day 40) and 25.0 [22-28] for LMM3 (n = 10, day 25). 
n = number of mice.
ND: not done.
a: p < 0.05 vs. control, Mann Whitney U-test
b: p < 0.01
c: p < 0.001
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as evaluated by direct microscopic observation and flow 
cytometry. In the same way, meta-tyrosine-treated mice 
did not display a lower humoral (titer of antibodies against 
sheep red blood cells) or cellular (delayed hypersensitivity) 
immune response (data not shown). More experiments 
measuring different physiologic variables not only in 
mice but also in other species such as rats and rabbits, in 
acute, sub-acute and chronic schedules of meta-tyrosine 
administration, will be necessary to demonstrate more 
accurately its lack of toxic-side effects.     
Surgical extirpation is the mainstay treatment of solid 
tumors and may be curative when metastatic cells have 
not already disseminated from the primary tumor. How-
ever, although it is recommended in most clinical cases, 
tumor removal may entail an undesired side effect: the 
acceleration of regional and distant (metastases) residual 
neoplastic disease. This effect may account for the disap-
pointingly modest survival benefits observed when surgery 
is used as a single strategy of treatment. Some investi-
gators have proposed some therapeutic options to limit 
metastatic growth after tumor removal, including the use 
of perioperative (instead of postoperative) chemotherapy, 
antioxidant agents, immunotherapy, and bio-modulation15, 
but to date, the results have not been as promissory as 
expected. An understanding of the phenomenon of CR, 
in particular the recent finding that meta-tyrosine and 
ortho-tyrosine would be the responsible for the most uni-
versal manifestation of CR13, 14, could help to overcome 
this problem. Data presented in this communication, 
suggest that, for therapeutic purposes, meta-tyrosine 
has many attractive features. For example, it exerts its 
anti-metastatic effect even at very low concentrations and 
does not exhibit any detectable toxic-side effects even 
at the highest therapeutic dose. In a former paper13 we 
have demonstrated that the anti-tumor effect mediated 
by meta- and ortho-tyrosine was associated –at least in 
part– with a very early inhibition of MAP/ERK signaling 
pathway and a subsequent decay of p-STAT3. We have 
also suggested that down-regulation of the expression of 
several genes engaged with cell proliferation and survival 
that are targets of pSTAT3, such as BCL-XL, cyclin D1, 
surviving and myc, among others, might induce tumor cells 
to enter into a state of dormancy in G0. Other mechanisms 
associated with an S-phase arrest, presumably related 
to the activation of an intra-S phase checkpoint, might 
also be involved14. A more profound understanding of 
the molecular basis of the antitumor effects mediated by 
meta-tyrosine and ortho-tyrosine, might help to develop 
new and less harmful means of managing malignant dis-
eases, especially by controlling the growth of metastases 
after the removal of a primary tumor, or after other surgi-
cal injuries or stressors that might promote the escape of 
metastases from dormancy. 
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LA TAPA
Digitalis purpurea L. Fotografía de Mark W. Skinner. Tomada en Cerro de la Muerte, Costa Rica, 8 500’. 
August 1980. Por cortesía y con el permiso del autor.
En: USDA, NRCS. 2014. The-PLANTS. Database. (http://plants.usda.gov; 27/11/2014. Nacional Plant 
Data Team, Greensboro, NC 27401-4901 USA.)
Digitalis purpurea L.; vulg. dedalera, digital, cartucho, etc. Nativa de Europa, Asia y NO de Africa, introducida 
en América; crece invasora en el sur de Chile y las provincias vecinas de Neuquén y Río Negro en Argentina. 
Sus raíces, tallos, hojas, flores y semillas contienen glucósidos cardíacos que inhiben el transporte trans-celular 
de Na+ y K+, tienen efecto inotrópico positivo y regulan la actividad del sistema nervioso autónomo. Introducida 
por William Withering (1741-1799) del conocimiento popular a la medicina convencional:
“En el año 1775, se pidió mi opinión acerca de una receta familiar para curar la hidropesía. Me dijeron que 
era un secreto por mucho tiempo guardado por una anciana de Shropshire, quien algunas veces curó cuando 
los más convencionales médicos habían fallado. También fui informado que los efectos que produce eran 
violentos vómitos y purgantes, pero los efectos diuréticos parecían haber sido pasados por alto. La medicina 
estaba compuesta por veinte o más hierbas diferentes pero no fue difícil, para una persona familiarizada en 
estos temas, percibir que la hierba activa no era otra que la dedalera.” William Withering. An account of the 
foxglove, some of its Medical uses: with practical remarks on dropsy, and other diseases. Printed by M. Swin-
ney, Birmingham, for G.G.J. and J. Robinson, London, 1785. En: www.botanicus.org/title/bl11202313; 
19-11-2014. Libre en línea.
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110-9; Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of heart failure in 
patients in sinus rhythm. Cochrane Database Syst Rev. 2014 Apr 28;4:CD002901.
doi:10.1002/14651858.CD002901.pub3.
